ALNY
ALNY clinical trials: ALNYLAM PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where ALNYLAM PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 95
- Trials linked
- 84
- As lead sponsor
- 11
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ALNY on the catalyst calendar · ALNY registry changes
- Primary completion Oct 23, 2030Sponsor estimateNo phase registeredNCT07358078DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World SettingAlnylam Pharmaceuticals · Transthyretin Amyloidosis With CardiomyopathyRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 12, 2030Sponsor estimateNo phase registeredNCT05040373Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramAlnylam Pharmaceuticals · Hereditary Transthyretin-mediated (hATTR) AmyloidosisRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2033Sponsor estimateNo phase registeredNCT04561518ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)Alnylam Pharmaceuticals · Transthyretin-Mediated AmyloidosisRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2030Sponsor estimatePhase 2NCT07636811A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)Alnylam Pharmaceuticals · Down Syndrome-Associated Alzheimer's Disease (DS-AD)RecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT06600321A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaAlnylam Pharmaceuticals · Advanced Hepatocellular CarcinomaRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2027Sponsor estimatePhase 3NCT07223203TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With...Alnylam Pharmaceuticals · Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2030Sponsor estimatePhase 1NCT07214727A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseAlnylam Pharmaceuticals · Alzheimer's DiseaseRecruitingALNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2030Sponsor estimatePhase 3NCT07052903TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyAlnylam Pharmaceuticals · Transthyretin Amyloidosis With CardiomyopathyRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 5, 2028Sponsor estimatePhase 1NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseAlnylam Pharmaceuticals · Huntington's DiseaseRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2030Sponsor estimateNo phase registeredNCT04883905ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)Alnylam Pharmaceuticals · Acute Hepatic PorphyriaRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2024ActualPhase 3NCT04153149HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyAlnylam Pharmaceuticals · Transthyretin Amyloidosis (ATTR) With CardiomyopathyActive, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 2NCT07575308HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBAlnylam Pharmaceuticals · Von Willebrand Disease (VWD)RecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2027Sponsor estimatePhase 2NCT07465224A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusAlnylam Pharmaceuticals · Type 2 Diabetes Mellitus (T2DM)Active, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2026Sponsor estimatePhase 1NCT07295717A Study to Evaluate ALN-4285 in Adult Healthy VolunteersAlnylam Pharmaceuticals · Healthy VolunteersRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2027Sponsor estimatePhase 1/Phase 2NCT06845202A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMAlnylam Pharmaceuticals · Obese or Overweight Healthy VolunteersActive, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 9, 2027Sponsor estimatePhase 2NCT06393712A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyAlnylam Pharmaceuticals · Cerebral Amyloid AngiopathyActive, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2027Sponsor estimatePhase 1NCT07624071A Study to Evaluate ALN-6222 in Participants With ObesityAlnylam Pharmaceuticals · ObesityRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2028Sponsor estimatePhase 2NCT07553442A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranAlnylam Pharmaceuticals · HypertensionRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2027Sponsor estimatePhase 1NCT07535606A Study to Evaluate ALN-4915 in Adult Healthy VolunteersAlnylam Pharmaceuticals · Healthy VolunteersActive, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 28, 2027Sponsor estimatePhase 1/Phase 2NCT07463846A Study to Evaluate ALN-2232 in Participants With ObesityAlnylam Pharmaceuticals · ObesityRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2030Sponsor estimatePhase 3NCT07181109Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for...Alnylam Pharmaceuticals · High Risk Cardiovascular DiseaseRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2029Sponsor estimatePhase 1NCT05231785A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADAlnylam Pharmaceuticals · Early-Onset Alzheimer DiseaseRecruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2028Sponsor estimatePhase 3NCT06679946A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyAlnylam Pharmaceuticals · Transthyretin Amyloidosis (ATTR) With CardiomyopathyEnrolling by invitationALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 5, 2028Sponsor estimatePhase 1/Phase 2NCT06659640A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Alnylam Pharmaceuticals · Hereditary Hemorrhagic TelangiectasiaActive, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2027Sponsor estimateNo phase registeredNCT06360289Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and...Alnylam Pharmaceuticals · Hereditary Amyloidosis, Transthyretin-RelatedActive, not recruitingALNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 70 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner